Active Ingredient History
Conatumumab is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL receptor 2 with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoid Tumor (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 1)
Hamartoma (Phase 1)
Hodgkin Disease (Phase 1)
Low Back Pain (Phase 1)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pain (Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Rectal Neoplasms (Phase 1/Phase 2)
Sarcoma (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue